Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-Label Expanded Access Program to Provide Giredestrant to Patients With ER+, HER2- Early or Metastatic Breast Cancer

NCT07643831 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT07643831
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07643831 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-Label Expanded Access Program to Provide Giredestrant to Patients With ER+, HER2- Early or Metastatic Breast Cancer
Lead sponsor
Genentech, Inc.
Phase
Expanded access
Overall status
Available
Start date
Not reported
Completion date
Not reported
Enrollment
Not reported
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

er+/her2- early or locally advanced/metastatic breast cancer